trientine has been researched along with Liver Failure in 2 studies
Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.
TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.
2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.
Liver Failure: Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hereditary hemochromatosis and Wilson disease are autosomal recessive storage disorders of iron and copper overload, respectively." | 2.50 | Metal storage disorders: Wilson disease and hemochromatosis. ( Kanwar, P; Kowdley, KV, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanwar, P | 1 |
| Kowdley, KV | 1 |
| Askari, FK | 1 |
| Greenson, J | 1 |
| Dick, RD | 1 |
| Johnson, VD | 1 |
| Brewer, GJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease[NCT01472874] | 8 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | g/dL (Mean) |
|---|---|
| Once a Day Trientine | 0.52 |
(NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | g/dL (Mean) |
|---|---|
| Once a Day Trientine | 0.54 |
Alanine transaminase (NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | U/L (Mean) |
|---|---|
| Once a Day Trientine | 50.89 |
Alanine transaminase (NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | U/L (Mean) |
|---|---|
| Once a Day Trientine | 41.38 |
(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | mcg/24h (Mean) |
|---|---|
| Once a Day Trientine | 0.52 |
(NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | mcg/24h (Mean) |
|---|---|
| Once a Day Trientine | 0.54 |
(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | mcg/24hr (Mean) |
|---|---|
| Once a Day Trientine | 313.4 |
(NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | mcg/24hr (Mean) |
|---|---|
| Once a Day Trientine | 287.9 |
The International Normalized Ratio (INR) is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy (NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | international normalized ratio (Mean) |
|---|---|
| Once a Day Trientine | 1.05 |
The International Normalized Ratio (INR) is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy (NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | international normalized ratio (Mean) |
|---|---|
| Once a Day Trientine | 0.99 |
(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | mcg/24hr (Mean) |
|---|---|
| Once a Day Trientine | 2214 |
(NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | mcg/24hr (Mean) |
|---|---|
| Once a Day Trientine | 1959 |
1 review available for trientine and Liver Failure
| Article | Year |
|---|---|
Metal storage disorders: Wilson disease and hemochromatosis.
Topics: Biopsy; Chelating Agents; Disease Progression; Genetic Predisposition to Disease; Genetic Testing; H | 2014 |
1 other study available for trientine and Liver Failure
| Article | Year |
|---|---|
Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc.
Topics: Adult; Drug Therapy, Combination; Female; Hepatolenticular Degeneration; Humans; Liver Failure; Male | 2003 |